The Myasthenia Gravis and Guillain–Barre Syndrome are both autoimmune disorders affecting the neuromuscular system, and they differ significantly in their pathophysiology and clinical presentation. MG is characterized by autoantibodies targeting ACh receptors at the neuromuscular junction, leading to muscle fatigue, while GBS involves an acute autoimmune attack on peripheral nerves, often triggered by preceding infections. Viral infections, particularly EBV, have been implicated in triggering or exacerbating these autoimmune reactions. Understanding the intricate relationship between viral infections and autoimmune dysregulation is crucial for improved diagnostic strategies and therapeutic interventions. Also, highlighting the common genetic factors helps researchers gain insights into the underlying mechanisms of autoimmune diseases and potentially identify targets for therapeutic intervention. Awareness of EBV's role in these diseases can lead to preventive strategies, such as antiviral treatments or vaccines, that could reduce the incidence or severity of EBV-associated autoimmune responses. Continued research and interdisciplinary collaboration are vital to understanding the mechanisms by which EBV influences MG and GBS, which can lead to more personalized treatment approaches, targeting the underlying viral infection, and investigating the immunological mechanisms, such as molecular mimicry and chronic infection, which can enhance diagnostic accuracy and lead to more effective treatments. Understanding the link between EBV and GBS can assist in identifying patients at risk following an EBV infection and guide the development of therapeutic strategies to prevent or mitigate GBS. Identifying and elucidating specific biomarkers and pathways will improve clinical protocols, public health guidelines, and education about the EBV-autoimmunity link, addressing genetic and environmental factors in disease etiology. Thus, additional research is warranted to enhance our knowledge of these disorders and provide more efficient treatment strategies.